Caring Brands, Inc. is a wellness consumer products company offering OTC and cosmetic products, including hair loss treatments, eczema/psoriasis solutions, vitiligo treatments, and suncare. The company reported nominal revenues of $4,215 and a net loss of $6,278,191 for the year ended December 31, 2025. Operating expenses significantly increased to $5,937,367 in 2025, up from $1,525,787 in 2024, driven by higher payroll, professional service fees, and intellectual property amortization. An impairment loss of $2,550,000 on intellectual property was recognized in 2025, reducing its carrying value to zero. Cash and cash equivalents increased to $2,189,232 as of December 31, 2025, primarily due to net proceeds of $3,235,692 from an initial public offering in November 2025. The Hair Enzyme Booster (JW-700) was launched on Amazon in October 2024 and NOVODX's e-commerce platform in December 2024, with minimal initial sales. Photocil, a vitiligo and psoriasis treatment, is targeted for a U.S. relaunch in 2026, having been removed from the U.S. market in February 2023 due to insufficient sales. CB-101, an eczema treatment, is undergoing reformulation, expected to complete in Q4 2025/Q1 2026, with an anticipated U.S. online launch in Q2 2026. The company identified material weaknesses in its internal controls over financial reporting related to period-end financial disclosure, reporting processes, and related party transaction identification. Subsequent to year-end, the company completed a private investment in public equity (PIPE) financing of approximately $3.6 million gross proceeds, involving Series A Convertible Preferred Stock and warrants. A significant portion of the PIPE proceeds, approximately $3.075 million, was used to repurchase 6,250,000 shares of common stock from insiders, including the CEO, Chairman's entity, and NovoDX.